RxDoctor Payments Data

Paul Soiya, MD

Internal Medicine · Scottsdale, AZNPI 1255426771

Payments from drug & device makers

$1,835in general payments, 2019–2025

Across 68 payments — averaging $26.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$487
  • GSK$412
  • AbbVie$256
  • Amgen$200
  • Boston Scientific$112
  • Almatica Pharma LLC$84
  • plus $283 from 12 others

What the payments were for

  • Food & beverage$1,835100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,835 in reported general payments places this provider in the 80th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$165,337
Medicare patients
342
Services billed
1,159

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban28$33,744
TradjentaLinagliptin22$31,236
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$30,408
JardianceEmpagliflozin14$21,777
FarxigaDapagliflozin Propanediol18$20,167
JanuviaSitagliptin Phosphate12$19,042
Rosuvastatin Calcium475$7,166
SynthroidLevothyroxine Sodium54$5,112
Levothyroxine Sodium401$4,229
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen116$4,004
Gabapentin109$3,616
Duloxetine Hcl97$3,575
Tamsulosin Hcl105$3,001
Potassium Chloride69$2,963
Liothyronine Sodium87$2,954

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$412$30,40834 claims
AstraZenecaFarxiga$487$20,16718 claims
AbbVieSynthroid$256$5,11254 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$30$4,229401 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →